港股異動 | 復鋭醫療科技(1696.HK)大漲17%再度破頂 年內股價翻近4倍
格隆匯5月13日丨醫美設備股復鋭醫療科技(1696.HK)再度拉昇漲17%,報16.34港元再創歷史新高價,總市值達72億港元。醫美概念股近期持續活躍,該股從4月以來持續拉昇上揚,累計漲幅高達250%,股價翻近4倍。4月中旬,復鋭醫療科技推出Alma PrimeXTM,基於主要意見領袖的反饋意見而開發的無創美體塑形及緊緻肌膚平台。此外,集團2020年下半年的收益較2019年下半年的收益增加3%,超過疫情前的業績。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.